3-Phenyl-1H-pyrazole-5-sulfonyl chloride | 1277168-02-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 3-Phenyl-1H-pyrazole-5-sulfonyl chloride
• 英文别名: 3-phenyl-1H-pyrazole-5-sulfonyl chloride
• CAS: 1277168-02-1
• 化学式: C₉H₇ClN₂O₂S
• 分子量: 242.686
• InChiKey: IBHNCBUMLPNXQE-UHFFFAOYSA-N

物化性质

• 沸点：
  482.8±33.0 °C(Predicted)
• 密度：
  1.489±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  71.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-(2-甲氧苯基)哌嗪 、 3-Phenyl-1H-pyrazole-5-sulfonyl chloride 在 N,N-二异丙基乙胺 作用下， 以 乙腈 为溶剂， 生成 1-(2-methoxyphenyl)-4-(3-phenyl-1H-pyrazol-5-ylsulfonyl)piperazine
  参考文献：
  名称：

  Discovery of 3-aryl-5-acylpiperazinyl-pyrazoles as antagonists to the NK3 receptor

  摘要：

  A series of 3-aryl-5-acylpiperazinyl-pyrazoles (e.g., 3a-b) initially identified through a high-throughput screening campaign using the aequorin Ca2+ bioluminescence assay as novel, potent small molecule antagonists of the G protein-coupled human tachykinin NK3 receptor (hNK3-R) is described. Preliminary profiling revealed poor plasma and metabolic stability for these structures in rodents. Further optimization efforts resulted in analogs with improved potency, stability, and pharmacokinetic properties as well as good brain permeability, for example, compounds 26 and 42. Unexpected cytotoxicity was observed in such N-Me pyrazole structures as compounds 41-42. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.02.033
• 作为产物：
  描述：

  5-苯基吡唑-3-羧酸乙酯 在 盐酸 、 二氧化硫 、 copper dichloride 作用下， 以 水 、 溶剂黄146 为溶剂， 生成 3-Phenyl-1H-pyrazole-5-sulfonyl chloride
  参考文献：
  名称：

  Discovery of 3-aryl-5-acylpiperazinyl-pyrazoles as antagonists to the NK3 receptor

  摘要：

  A series of 3-aryl-5-acylpiperazinyl-pyrazoles (e.g., 3a-b) initially identified through a high-throughput screening campaign using the aequorin Ca2+ bioluminescence assay as novel, potent small molecule antagonists of the G protein-coupled human tachykinin NK3 receptor (hNK3-R) is described. Preliminary profiling revealed poor plasma and metabolic stability for these structures in rodents. Further optimization efforts resulted in analogs with improved potency, stability, and pharmacokinetic properties as well as good brain permeability, for example, compounds 26 and 42. Unexpected cytotoxicity was observed in such N-Me pyrazole structures as compounds 41-42. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.02.033